Roche vet Jean-Jacques Ga­raud woos in­ter­na­tion­al be­liev­ers in his French star­tup's take on sep­tic shock

Jean-Jacques Ga­raud

When Jean-Jacques Ga­raud left the top role in re­search and ear­ly de­vel­op­ment at Roche to build and ad­vise ear­ly-stage biotechs in his na­tive Paris, one fledg­ling quick­ly drew close to his heart.

The start­up, In­otrem, was de­vel­op­ing an im­munother­a­py to treat sep­tic shock. Hav­ing trained as a crit­i­cal care physi­cian be­fore mov­ing to Scher­ing-Plough and then No­var­tis, Ga­raud was all too fa­mil­iar with the dearth of treat­ments for sep­sis, which is dead­ly even in de­vel­oped coun­tries, claim­ing more than a quar­ter-mil­lion deaths in the US each year.

To­geth­er with co-founders Sébastien Gi­bot and Marc De­rive (De­rive did his PhD at Gi­bot’s lab and is now In­otrem’s CSO), he swift­ly gath­ered €18 mil­lion from French VCs An­dera Part­ners and Sofinno­va Part­ners, as well as the trans­fer seed fund known as In­serm and Swiss play­er Bio­Med­In­vest. But for the next round of fund­ing, Ga­raud told Phar­ma Board­room ear­li­er this year, he’d be look­ing to bring in in­ter­na­tion­al in­vestors out­side of France and Eu­rope.

Marc De­rive

And bring in in­ter­na­tion­al in­vestors he did. Morn­ing­side Ven­tures, which traces its roots to Hong Kong, is lead­ing In­otrem’s €39 mil­lion Se­ries B. New York-based In­vus al­so joined the syn­di­cate.

“This fi­nanc­ing val­i­dates the po­ten­tial of our tech­nol­o­gy plat­form cen­tered on the TREM-1 path­way and of our lead drug can­di­date for sep­tic shock, nan­gi­botide, which will be en­ter­ing a large Phase IIb clin­i­cal tri­al lat­er this year,” Ga­raud said in a state­ment.

Char­ac­ter­ized by dan­ger­ous­ly low blood pres­sure, sep­tic shock is the most se­vere com­pli­ca­tion of sep­sis, which oc­curs when the body mounts an over­whelm­ing re­sponse to an in­fec­tion, lead­ing to or­gan fail­ures. While an­tibi­otics can help tamp down the in­fec­tion, nei­ther it nor sup­port­ive care ad­dress­es the un­der­ly­ing shock.

In­otrem’s hy­poth­e­sis is that by in­hibit­ing TREM-1 — a re­cep­tor ex­pressed on myeloid cells — its pep­tide drug can mod­u­late the im­mune at­tack with­out com­plete­ly stop­ping the in­flam­ma­to­ry re­sponse from clear­ing harm­ful bac­te­ria.

The field is not packed, but the biotech is not alone ei­ther. Berlin-based Adrenomed is tack­ling a tar­get called adrenomedullin, while Medicxi-backed UK start­up Crit­i­cal Pres­sure reck­ons hit­ting DDAH1 is the way to go.

With the new fund­ing, In­otrem plans to launch a glob­al Phase IIb tri­al to test that the­o­ry, re­cruit­ing 450 pa­tients and test­ing two dos­es of nan­gi­botide against stan­dard of care and place­bo.

Keep­ing his phar­ma con­nec­tions close, Ga­raud has al­so se­cured a part­ner­ship with Roche on a com­pan­ion di­ag­nos­tic tool based con­cen­tra­tion of TREM-1 in pa­tients.

In ad­di­tion to sep­tic shock, In­otrem is al­so de­vel­op­ing its TREM-1 drugs in car­dio­vas­cu­lar dis­eases and chron­ic in­flam­ma­to­ry con­di­tions.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Deborah Dunsire. Lundbeck

Deb­o­rah Dun­sire is pay­ing $2B for a chance to leap di­rect­ly in­to a block­buster show­down with a few of the world's biggest phar­ma gi­ants

A year after taking the reins as CEO of Lundbeck, Deborah Dunsire is making a bold bid to beef up the Danish biotech’s portfolio of drugs in what will likely be a direct leap into an intense rivalry with a group of giants now carving up a growing market for new migraine drugs.

Bright and early European time the company announced that it will pay up to about $2 billion to buy Alder, a little biotech that is far along the path in developing a quarterly IV formulation for a CGRP drug aimed at cutting back the number of crippling migraines patients experience each month.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Lisa M. DeAngelis, MSKCC

MSK picks brain can­cer ex­pert Lisa DeAn­ge­lis as its next CMO — fol­low­ing José Basel­ga’s con­tro­ver­sial ex­it

It’s official. Memorial Sloan Kettering has picked a brain cancer expert as its new physician-in-chief and CMO, replacing José Baselga, who left under a cloud after being singled out by The New York Times and ProPublica for failing to properly air his lucrative industry ties.

His replacement, who now will be in charge of MSK’s cutting-edge research work as well as the cancer care delivered by hundreds of practitioners, is Lisa M. DeAngelis. DeAngelis had been chair of the neurology department and co-founder of MSK’s brain tumor center and was moved in to the acting CMO role in the wake of Baselga’s departure.

Penn team adapts CAR-T tech, reengi­neer­ing mouse cells to treat car­diac fi­bro­sis

After establishing itself as one of the pioneer research centers in the world for CAR-T cancer therapies, creating new attack vehicles to eradicate cancer cells, a team at Penn Medicine has begun the tricky transition of using the basic technology for heart repair work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Tal Zaks. Moderna

The mR­NA uni­corn Mod­er­na has more ear­ly-stage hu­man da­ta it wants to show off — reach­ing new peaks in prov­ing the po­ten­tial

The whole messenger RNA field has attracted billions of dollars in public and private investor cash gambled on the prospect of getting in on the ground floor. And this morning Boston-based Moderna, one of the leaders in the field, wants to show off a few more of the cards it has to play to prove to you that they’re really in the game.

The whole hand, of course, has yet to be dealt. And there’s no telling who gets to walk with a share of the pot. But any cards on display at this point — especially after being accused of keeping its deck under lock and key — will attract plenty of attention from some very wary, and wired, observers.

“In terms of the complexity and unmet need,” says Tal Zaks, the chief medical officer, “this is peak for what we’ve accomplished.”

Moderna has two Phase I studies it wants to talk about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

It's not per­fect, but it's a good start: FDA pan­elists large­ly en­dorse Aim­mune's peanut al­ler­gy ther­a­py

Two days after a fairly benign review from FDA staff, an independent panel of experts largely endorsed the efficacy and safety of Aimmune’s peanut allergy therapy, laying the groundwork for approval with a risk evaluation and mitigation strategy (REMS).

Traditionally, peanut allergies are managed by avoidance, but the threat of accidental exposure cannot be nullified. Some allergists have devised a way to dose patients off-label with peanut protein derived from supermarket products to wean them off their allergies. But the idea behind Aimmune’s product was to standardize the peanut protein, and track the process of desensitization — so when accidental exposure in the real world invariably occurs, patients are less likely to experience a life-threatening allergic reaction.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Rit­ter bombs fi­nal PhI­II for sole lac­tose in­tol­er­ance drug — shares plum­met

More than two years ago Ritter Pharmaceuticals managed to find enough silver lining in its Phase IIb/III study — after missing the top-line mark — to propel its lactose intolerance toward a confirmatory trial. But as it turned out, the enthusiasm only set the biotech and its investors up to be sorely disappointed.

This time around there’s little left to salvage. Not only did RP-G28 fail to beat placebo in reducing lactose intolerance symptoms, patients in the treatment group actually averaged a smaller improvement. On a composite score measuring symptoms like abdominal pain, cramping, bloating and gas, patients given the drug had a mean reduction of 3.159 while the placebo cohort saw a 3.420 drop on average (one-sided p-value = 0.0106).

Ear­ly snap­shot of Ad­verum's eye gene ther­a­py sparks con­cern about vi­sion loss

An early-stage update on Adverum Biotechnologies’ intravitreal gene therapy has triggered investor concern, after patients with wet age-related macular degeneration (AMD) saw their vision deteriorate, despite signs that the treatment is improving retinal anatomy.

Adverum, on Wednesday, unveiled 24-week data from the OPTIC trial of its experimental therapy, ADVM-022, in six patients who have been administered with one dose of the therapy. On average, patients in the trial had severe disease with an average of 6.2 anti-VEGF injections in the eight months prior to screening and an average annualized injection frequency of 9.3 injections.

Alex Ar­faei trades his an­a­lyst's post for a new role as biotech VC; Sanofi vet heads to Vi­for

Too often, Alex Arfaei arrived too late. 

An analyst at BMO Capital Markets, he’d meet with biotech or pharmaceutical heads for their IPO or secondary funding and his brain, trained on a biology degree and six years at Merck and Endo, would spring with questions: Why this biomarker? Why this design? Why not this endpoint? Not that he could do anything about it. These execs were coming for clinical money; their decisions had been made and finalized long ago.